Fitch Ratings says it believes biosimilars will be accepted faster in the US than has been the case in Europe. They believe the US infrastructure is attuned to switching branded drugs for generic -- and that third party payers and pharmacy managers are powerfully motivated to do so. The motivation coming the desire to save money and resulting bonus incentives.
Based on the potential of biosimilars to save money -- as biologic drugs are among the world's most expensive -- there is even more motivation potential according to Fitch. European uptake has historically beenmuch slower as doctors, pharmacists and patients have been more resistant. In the US however, it isexpected that adoption will be more rapid and that there may even be market expansion due to lower prices (i.e. elastic demand). See PharmaTimes.
This is all hypothetical until we actually get a biosimilar approved and on the US market. I, however, believe payers and the government have powerful economic incentives to make this happen.
Posted by Bruce Lehr Oct 10th 2013.